Linda M. C. Koene
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linda M. C. Koene has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ype Elgersma
Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications Carmen B. Schäfer
Affiliation Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands
1 shared publication- Diana C. Rotaru
Department of Clinical Genetics and
1 shared publication - Eva Niggl
Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication - Geeske M. van Woerden
Erasmus MC
1 shared publication - Ilse Wallaard1 shared publication
Latest Publications
- Open Access
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis
Tuberous sclerosis complex (TSC), caused by heterozygous mutations in TSC1 or TSC2 , frequently results in intractable epilepsy. Here, we made use of an inducible Tsc1 -knockout mouse model, allowing us to study electrophysiological and molecular changes of Tsc1 -induced epileptogenesis over time. We recorded from pyramidal neurons in the hippocampus and somatosensory cortex (L2/L3) and combined this with an analysis of transcriptome changes during epileptogenesis. Deletion of Tsc1 resulted in hippocampus-specific changes in excitability and adaptation, which emerged before seizure onset and progressed over time. All phenotypes were rescued after early treatment with rapamycin, an mTOR inhibitor. Later in epileptogenesis, we observed a hippocampal increase of excitation-to-inhibition ratio. These cellular changes were accompanied by dramatic transcriptional changes, especially after seizure onset. Most of these changes were rescued upon rapamycin treatment. Of the genes encoding ion channels or belonging to the Gene Ontology term action potential, 27 were differentially expressed just before seizure onset, suggesting a potential driving role in epileptogenesis. Our data highlight the complex changes driving epileptogenesis in TSC, including the changed expression of multiple ion channels. Our study emphasizes inhibition of the TSC/mTOR signaling pathway as a promising therapeutic approach to target epilepsy in patients with TSC.
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
Open AccessIdentifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis
Tuberous sclerosis complex (TSC), caused by heterozygous mutations in TSC1 or TSC2 , frequently results in intractable epilepsy. Here, we made use of an inducible Tsc1 -knockout mouse model, allowing us to study electrophysiological and molecular changes of Tsc1 -induced epileptogenesis over time. We recorded from pyramidal neurons in the hippocampus and somatosensory cortex (L2/L3) and combined this with an analysis of transcriptome changes during epileptogenesis. Deletion of Tsc1 resulted in hippocampus-specific changes in excitability and adaptation, which emerged before seizure onset and progressed over time. All phenotypes were rescued after early treatment with rapamycin, an mTOR inhibitor. Later in epileptogenesis, we observed a hippocampal increase of excitation-to-inhibition ratio. These cellular changes were accompanied by dramatic transcriptional changes, especially after seizure onset. Most of these changes were rescued upon rapamycin treatment. Of the genes encoding ion channels or belonging to the Gene Ontology term action potential, 27 were differentially expressed just before seizure onset, suggesting a potential driving role in epileptogenesis. Our data highlight the complex changes driving epileptogenesis in TSC, including the changed expression of multiple ion channels. Our study emphasizes inhibition of the TSC/mTOR signaling pathway as a promising therapeutic approach to target epilepsy in patients with TSC.
- Open Access
- 26 May 2021
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 19 (5) , e3001279
RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity
Hyperactivation of the mammalian target of rapamycin (mTOR) pathway can cause malformation of cortical development (MCD) with associated epilepsy and intellectual disability (ID) through a yet unknown mechanism. Here, we made use of the recently identified dominant-active mutation inRas Homolog Enriched in Brain 1(RHEB), RHEBp.P37L, to gain insight in the mechanism underlying the epilepsy caused by hyperactivation of the mTOR pathway. Focal expression of RHEBp.P37L in mouse somatosensory cortex (SScx) results in an MCD-like phenotype, with increased mTOR signaling, ectopic localization of neurons, and reliable generalized seizures. We show that in this model, the mTOR-dependent seizures are caused by enhanced axonal connectivity, causing hyperexcitability of distally connected neurons. Indeed, blocking axonal vesicle release from the RHEBp.P37L neurons alone completely stopped the seizures and normalized the hyperexcitability of the distally connected neurons. These results provide new evidence of the extent of anatomical and physiological abnormalities caused by mTOR hyperactivity, beyond local malformations, which can lead to generalized epilepsy.
- 26 May 2021
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 19 (5) , e3001279
Open AccessRHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity
Hyperactivation of the mammalian target of rapamycin (mTOR) pathway can cause malformation of cortical development (MCD) with associated epilepsy and intellectual disability (ID) through a yet unknown mechanism. Here, we made use of the recently identified dominant-active mutation inRas Homolog Enriched in Brain 1(RHEB), RHEBp.P37L, to gain insight in the mechanism underlying the epilepsy caused by hyperactivation of the mTOR pathway. Focal expression of RHEBp.P37L in mouse somatosensory cortex (SScx) results in an MCD-like phenotype, with increased mTOR signaling, ectopic localization of neurons, and reliable generalized seizures. We show that in this model, the mTOR-dependent seizures are caused by enhanced axonal connectivity, causing hyperexcitability of distally connected neurons. Indeed, blocking axonal vesicle release from the RHEBp.P37L neurons alone completely stopped the seizures and normalized the hyperexcitability of the distally connected neurons. These results provide new evidence of the extent of anatomical and physiological abnormalities caused by mTOR hyperactivity, beyond local malformations, which can lead to generalized epilepsy.